| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mahomi Kuroiwa, Miho Hamada, Eriko Hieda, Takahide Shuto, Naoki Sotogaku, Marc Flajolet, Gretchen L Snyder, Joseph P Hendrick, Allen Fienberg, Akinori Nish. Muscarinic receptors acting at pre- and post-synaptic sites differentially regulate dopamine/DARPP-32 signaling in striatonigral and striatopallidal neurons. Neuropharmacology. vol 63. issue 7. 2013-02-12. PMID:22971543. |
the increase in darpp-32 phosphorylation was completely abolished either by a dopamine d(1) receptor antagonist (sch23390), tetrodotoxin, genetic deletion of m5 receptors, muscarinic toxins for m1 and m4 receptors, or 6-hydroxydopamine lesioning of dopaminergic neurons, whereas it was enhanced by nicotine. |
2013-02-12 |
2023-08-12 |
mouse |
| Massimo Grilli, Maria Summa, Alessia Salamone, Guendalina Olivero, Stefania Zappettini, Silvia Di Prisco, Marco Feligioni, Cesare Usai, Anna Pittaluga, Mario March. In vitro exposure to nicotine induces endocytosis of presynaptic AMPA receptors modulating dopamine release in rat nucleus accumbens nerve terminals. Neuropharmacology. vol 63. issue 5. 2013-01-14. PMID:22771975. |
the nach-ampa receptor-receptor interaction was not limited to dopaminergic terminals since nicotine pre-exposure also affected the presynaptic ampa receptors controlling hippocampal noradrenaline release, but not the presynaptic ampa receptors controlling gaba and acetylcholine release. |
2013-01-14 |
2023-08-12 |
rat |
| Tanuja Bordia, Maya Hrachova, Matthew Chin, J Michael McIntosh, Maryka Qui. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum. The Journal of pharmacology and experimental therapeutics. vol 342. issue 2. 2012-12-21. PMID:22550286. |
extensive evidence indicates that varenicline reduces nicotine craving and withdrawal symptoms by modulating dopaminergic function at α4β2* nicotinic acetylcholine receptors (nachrs) (the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex). |
2012-12-21 |
2023-08-12 |
rat |
| Xiomara A Perez, Jason Ly, J Michael McIntosh, Maryka Qui. Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbens. The Journal of pharmacology and experimental therapeutics. vol 342. issue 2. 2012-12-21. PMID:22562772. |
although recent work suggests that α6β2* nicotinic acetylcholine receptors (nachrs) play a dominant role in dopaminergic function in rodent nucleus accumbens, the effects of long-term nicotine exposure remain to be determined. |
2012-12-21 |
2023-08-12 |
monkey |
| Luis A Natividad, Matthew W Buczynski, Loren H Parsons, Oscar V Torres, Laura E O'Del. Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal. Journal of neurochemistry. vol 123. issue 4. 2012-12-21. PMID:22905672. |
differential dopaminergic responses to nicotine are thought to underlie these age-related effects, as adolescent rats experience lower withdrawal-related deficits in nucleus accumbens (nacc) dopamine versus adults. |
2012-12-21 |
2023-08-12 |
rat |
| Die Zhang, Ming Gao, Dan Xu, Wei-Xing Shi, Boris S Gutkin, Scott C Steffensen, Ronald J Lukas, Jie W. Impact of prefrontal cortex in nicotine-induced excitation of ventral tegmental area dopamine neurons in anesthetized rats. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 36. 2012-11-16. PMID:22956827. |
systemic administration of nicotine increases dopaminergic (da) neuron firing in the ventral tegmental area (vta), which is thought to underlie nicotine reward. |
2012-11-16 |
2023-08-12 |
rat |
| Elakeche Ella, Naomi Sato, Daisuke Nishizawa, Shinji Kageyama, Hidetaka Yamada, Nobuya Kurabe, Keiko Ishino, Hong Tao, Fumihiko Tanioka, Akiko Nozawa, Chen Renyin, Kazuya Shinmura, Kazutaka Ikeda, Haruhiko Sugimur. Association between dopamine beta hydroxylase rs5320 polymorphism and smoking behaviour in elderly Japanese. Journal of human genetics. vol 57. issue 6. 2012-11-07. PMID:22513716. |
the dopaminergic brain pathway is involved in many addictive behaviours, hence represents a good candidate in the study of smoking behaviour and nicotine addiction. |
2012-11-07 |
2023-08-12 |
human |
| Xavier Gallego, Susanna Molas, Alejandro Amador-Arjona, Michael J Marks, Noemí Robles, Patricia Murtra, Lluís Armengol, Rubén D Fernández-Montes, Mònica Gratacòs, Martí Pumarola, Roberto Cabrera, Rafael Maldonado, Josefa Sabrià, Xavier Estivill, Mara Diersse. Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino acids. vol 43. issue 2. 2012-11-06. PMID:22101982. |
moreover, they exhibited increased sensitivity to the pharmacological effects of nicotine along with higher activation of the medial habenula and reduced activation of dopaminergic neurons in the ventral tegmental area after acute nicotine administration. |
2012-11-06 |
2023-08-12 |
mouse |
| Ns Ambhore, S Antony, Jk Mali, Am Kanhed, Ar Bhalerao, S Bhojra. Pharmacological and biochemical interventions of cigarette smoke, alcohol, and sexual mating frequency on idiopathic rat model of Parkinson's disease. Journal of young pharmacists : JYP. vol 4. issue 3. 2012-11-01. PMID:23112537. |
earlier literature from different publisher suggested that nicotine and cigarette smoke can protect the dopaminergic neurons in the substantia nigra against mptp toxicity. |
2012-11-01 |
2023-08-12 |
rat |
| Patricia Muñoz, Sandro Huenchuguala, Irmgard Paris, Carlos Cuevas, Monica Villa, Pablo Caviedes, Juan Segura-Aguilar, Yousef Tizab. Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. Neurotoxicity research. vol 22. issue 2. 2012-10-10. PMID:22528249. |
nicotine, on the other hand, may offer protective effects against dopaminergic cell damage induced by various neurotoxins including mptp and salsolinol. |
2012-10-10 |
2023-08-12 |
Not clear |
| A Batra, G Gelfort, M Bartels, H Smoltczyk, G Buchkremer, O Riess, L Schöl. The dopamine D2 receptor (DRD2) gene-a genetic risk factor in heavy smoking? Addiction biology. vol 5. issue 4. 2012-10-02. PMID:20575861. |
indications of a genetic predisposition to nicotine dependence have been derived from numerous epidemiological data and from individual genetic studies suggesting the involvement of the dopaminergic d2 receptor. |
2012-10-02 |
2023-08-12 |
Not clear |
| P Eriksson, A Fredriksso. Neonatal exposure to 2,2',5,5'-tetrachlorobiphenyl causes increased susceptibility in the cholinergic transmitter system at adult age. Environmental toxicology and pharmacology. vol 1. issue 3. 2012-10-02. PMID:21781685. |
neonatal exposure of male nmri mice on postnatal day 10 to 2,2',5,5'-tetrachlorobiphenyl (4.1 mg/kg body weight, per os) was shown to alter the response to a cholinergic agent, nicotine, at an adult age of 4 months, but not to d-amphetamine, an agent known to affect the dopaminergic system. |
2012-10-02 |
2023-08-12 |
mouse |
| C Reavill, I P Stolerma. Interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159140. |
interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. |
2012-10-02 |
2023-08-12 |
rat |
| C Reavill, I P Stolerma. Interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159140. |
biochemical and electrophysiological studies have suggested that nicotine may interact with dopaminergic systems so as to enhance the release and utilization of dopamine. |
2012-10-02 |
2023-08-12 |
rat |
| C Reavill, I P Stolerma. Interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159140. |
the results suggest that there may be a minor component of the nicotine discriminative stimulus that is mediated, indirectly, through a dopaminergic mechanism. |
2012-10-02 |
2023-08-12 |
rat |
| M R Zarrindast, A Zarghi, A Amir. Nicotine-induced hypothermia through an indirect dopaminergic mechanism. Journal of psychopharmacology (Oxford, England). vol 9. issue 1. 2012-10-02. PMID:22298689. |
it is concluded that nicotine may cause a fall in core body temperature through a central dopaminergic mechanism. |
2012-10-02 |
2023-08-12 |
mouse |
| Allison B Gold, E Paul Wileyto, Adriana Lori, David Conti, Joseph F Cubells, Caryn Lerma. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 7. 2012-09-21. PMID:22373943. |
galanin modulates dopaminergic neurotransmission in the mesolimbic dopamine system, thereby influencing the rewarding effects of nicotine. |
2012-09-21 |
2023-08-12 |
Not clear |
| Jun Kawamata, Syuuichirou Suzuki, Shun Shimoham. α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300030. |
examining the distribution of subtypes of nicotinic acetylcholine receptors (nachrs) in dopaminergic neurons of nigrostriatal system and its change in pd patients is quite important to elucidate possible neuroprotective cascade triggered by nicotine. |
2012-09-17 |
2023-08-12 |
Not clear |
| Claire Thiriez, Gabriel Villafane, Frédérique Grapin, Gilles Fenelon, Philippe Remy, Pierre Cesar. Can nicotine be used medicinally in Parkinson's disease? Expert review of clinical pharmacology. vol 4. issue 4. 2012-09-04. PMID:22114853. |
nicotine, a major component of tobacco smoke, could exert either nonreceptor-mediated biological effects or, more importantly, act on the different subtypes of nicotinic brain receptors, in particular those associated with the nigrostriatal dopaminergic pathway. |
2012-09-04 |
2023-08-12 |
Not clear |
| Claire Thiriez, Gabriel Villafane, Frédérique Grapin, Gilles Fenelon, Philippe Remy, Pierre Cesar. Can nicotine be used medicinally in Parkinson's disease? Expert review of clinical pharmacology. vol 4. issue 4. 2012-09-04. PMID:22114853. |
there is now robust experimental evidence for a neuroprotective effect of nicotine upon dopaminergic neurons. |
2012-09-04 |
2023-08-12 |
Not clear |